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Withdrawal in Inflammatory Bowel
Disease
Edouard Louis*
Department of Gastroenterology, University and CHU Liège, Liège, Belgium
There is currently no cure for inflammatory bowel disease. Most recent treatments
and treatment strategies allow for healing intestinal lesions and maintaining steroid-free
remission in a subset of patients. These patients and their doctors often ask themselves
whether the treatment could be withdrawn. Several studies in both Crohn’s disease and
ulcerative colitis have demonstrated a risk of relapse, which varies between 20 and 50%
at 1 year and between 50 and 80% beyond 5 years. These numbers clearly highlight
that stopping therapy should not be a systematically proposed strategy in those remitting
patients. Nevertheless, they also indicate that a minority of patients may not relapse over
mid-term and that those who have relapsed may have benefited from a drug-free period
before being treated again for a new cycle of treatment. In this context, it would be good
to optimally select patients who can be candidates for a successful treatment withdrawal.
The criteria impacting this decision are as follows: the risk of relapse (linked to factors like
mucosal healing and biomarkers), the consequence of a potential relapse, the tolerance
and potential side effects of therapy, patients’ priorities and preferences, and the costs.
Integration of these parameters allows for the proposal of a decisional algorithm that may
help the patients and doctors to make an appropriate decision for their individual case.
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INTRODUCTION
The cure for a disease is logically considered as a main situation where a treatment withdrawal
can be decided. However, there is currently no cure for inflammatory bowel disease (IBD). In
our current conception, those are multifactorial polygenic diseases (1). Therefore, a cure is highly
unlikely. What we could imagine is to be able to sufficiently modify the environment to be
able to stop the ongoing immuno-inflammatory process (2). There are two limitations to this
possibility: first, the self-perpetuation of inflammationwould be installed and not be possible to stop
even retrieving environmental triggers, and second, the cumulated tissue damage would generate
symptoms. This second point should not be an obstacle to treatment withdrawal but would rather
require complementary symptomatic treatments. Beyond this, a treatment withdrawal would also
make sense when the benefit of the treatment is lower than its risk and/or cost. Most often, it
is considered that cost here is a political health care system or a pragmatic insurance company
decision that cannot be made at the level of individual patients. The situation where it could be
decided on an individual patient basis is when the patient is not covered for his/her medical fees
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and has to decide himself or herself how to spend money,
including for health care. This situation is very rare in western
Europe. Nevertheless, public or private health institutions have
important decision to make in this field. For them, the
benefit/cost ratio is certainly relevant and has to be taken into
account. For the physician, it is thus usually the benefit/risk
ratio that is dominant. Assessing this is not an easy task as
the physician thus needs to integrate and compute at the same
time the risk of ongoing drug therapy and the benefit of this
therapy. Furthermore, the risk linked to treatment withdrawal
is not limited to the risk of relapse. We also have to consider
the probability of rapidly recovering remission after retreatment,
and if the response to retreatment was not appropriate, the
consequences of the disease flare, including the risk of surgical
resection. It is even more complicated as the physician should
also integrate the patient’s preferences and priorities. Indeed,
the acceptance of the risk of side effects and the risk of disease
progression may vary from patient to patient.
The aims of this review article are to illustrate the most
important factors to consider when contemplating treatment
withdrawal in IBD and to propose a way to integrate these various
factors. The benefit/risk and benefit/cost ratios of mesalazine has
been recently reviewed and probably remains positive over time
(3). Therefore, we will focus on biologic and immunomodulator
withdrawal. As far as biologic therapy is concerned, there are
currently essential data on anti-tumor necrosis factor (anti-TNF)
and concerning an immunomodulator, essentially purines.
THE RISK OF RELAPSE AFTER
TREATMENT WITHDRAWAL IN IBD
The risk of relapse after treatment withdrawal is probably a
point that has been best documented. Overall, both in Crohn’s
disease (CD) and in ulcerative colitis (UC), the risk of relapse
after stopping anti-TNF is around 50% over 1–2 years (4, 5).
It is probably increasing with time of follow-up and has been
described around 70–80% in CD after 7–8 years (6). Withdrawal
of immunomodulator seems to be associated with a slower
relapse risk (7). It has been estimated to be around 20–30%
after 1–2 years. However, here again it progresses with time and
reaches >50% after 5 years (8). After retreatment, over the short
term, most of the patients respond to resuming both anti-TNF
or immunomodulator (4, 5, 9). For anti-TNF, a small proportion
will lose response over time, but a substantial number of them
are still effectively treated with the same drug more than 5 years
later (6). In UC, up to 10% of withdrawn patients may have to
undergo colectomy within 1 year after anti-TNF withdrawal (10),
while this proportion seems lower in CD with also 10–15% but
only over 7–8 years (6). These risks are too high to propose a
treatment withdrawal in all patients reaching sustained steroid-
free remission in IBD. This assertion is reinforced by patients’
survey highlighting the fact that among them, the majority would
only accept a maximum risk of relapse of 25% (11). According
to this, we should try to identify a subpopulation with a risk
of relapse lower than 25%. Predictors of relapse have been
studied in many studies with anti-TNF and immunomodulators.
No data are available for vedolizumab or ustekinumab. These
predictors have recently been extensively reviewed, and results
are heterogeneous (3–5, 12). This heterogeneity is explained
by the heterogeneity of the study populations, including the
differences between prospective trials and retrospective analyses
of routine practice populations. In routine practice, the selection
of the population for treatment withdrawal is more stringent,
focusing on, for example, patients in endoscopic remission, while
prospective trials may also have included patients still having
endoscopic lesions. A certain heterogeneity can also be explained
by predictors that have been studied, particularly in retrospective
studies where only a limited amount of variables was available.
Results were also different when considering the withdrawal of
anti-TNF or immunomodulator and in CD or in UC. In general,
predictors have been more difficult to disclose in UC than in
CD. In the largest retrospective study so far, while a series of
predictors could be found for CD, none was found for UC
(12). Among the most prominent predictors are the direct or
indirect signs of persisting disease activity: endoscopic lesions,
elevated bloodmarkers of inflammation (C-reactive protein), and
elevated stool markers of inflammation (fecal calprotectin) (3–5).
Other prominent predictors are linked to ongoing treatment: co-
treatment with an immunomodulator and low or undetectable
trough level of anti-TNF were associated with a lower risk of
relapse when stopping this anti-TNF (3–5). According to this,
persisting endoscopic lesions and trough level of the drug are
often considered as key factors for clinicians to be assessed
in clinical practice before considering drug withdrawal. Albeit
important, they only represent part of the problem. Indeed, in
the STORI cohort, even in patients with full endoscopic healing,
the relapse rate after infliximab withdrawal was 30% over 1 year
(as compared to 45% in the general population and 10% in the
low-risk group). Likewise, a low or undetectable trough level of
infliximab has been associated with a decreased risk of relapse
upon withdrawal. This makes sense and probably corresponds
to situations where infliximab has a minor impact on the
maintenance of remission. It is, however, not so straightforward,
as a low trough does not necessarily mean no effect of the drug.
This drug may still generate relevant exposition linked to peak
concentration and area under the curve of this concentration
over 4–8 weeks. In the STORI cohort, the infliximab level was not
associated with the risk of relapse in univariate analysis but was
only selected in the multivariate model. Other factors have been
proposed, but they either also indirectly reflect ongoing disease
activity or current treatment or are more difficult to explain and
need to be confirmed. Smoking, which has often been associated
with bad outcome in CD, has only been found predictive of
relapse after stopping anti-TNF in one study (3). Histologic
remission, which is becoming an important outcome in UC and
which is questioned in CD, has not been adequately studied as a
predictor after treatment withdrawal in IBD. According to these
results, the best candidates for anti-TNF withdrawal would be
patients with clinically, biologically, and endoscopically inactive
disease and with immunomodulator co-treatment and/or low-
undetectable biologic drug level (Table 1). In the STORI cohort, it
represented 15–20% of the patients recruited in the trial (9). This
gives an estimation of the proportion of patients among those
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TABLE 1 | Most important factors favoring treatment withdrawal in IBD.
Factors associated with a lower risk of relapse
Mucosal healing (mainly CD and anti-TNF)
Normal CRP (mainly CD)
Low fecal calprotectin (<250µg/g) (mainly CD and anti-TNF)
Low or undetectable trough levels of biologic treatment (mainly CD and anti-TNF)
Immunomodulator co-treatment (mainly CD and anti-TNF)
Factors associated with low cumulative intestinal tissue damage
No complex perianal disease
No severe rectal disease
No intestinal or colonic stricture
No history of intra-abdominal abscess or fistula
Limited extent of the disease in the past
Factors associated with increased risk of treatment side effects
Older age (>65 years old)
Co-morbidities favoring infection or the risk of cancer
Side effects attributed to the treatment
Patient’s preference
Pregnancy
High fear of treatment side effects
Low fear of surgery




For the factors associated with a lower risk of relapse, the situations for which evidence
is the strongest are put under brackets.
IBD, inflammatory bowel disease; CD, Crohn’s disease; TNF, tumor necrosis factor; CRP,
C-reactive protein.
having longstanding steroid-free remission under combination
therapy, with a low risk of relapse. However, as the retreatment
upon relapse seems safe and effective and as a substantial
number of patients may benefit from at least temporary drug
withdrawal, the candidates for temporary withdrawal may be
more numerous.
THE CONSEQUENCES OF THE RELAPSE
AFTER TREATMENT WITHDRAWAL IN IBD
Relapsing after biologic or immunomodulator treatment
withdrawal would be a minor problem if a remission could
rapidly be re-captured and without disease progression leading
to the need of a surgical resection. The situation is obviously
much different if the relapse is associated with the development
of a complication, like a stricture, an abscess, or a fistula in CD,
and an acute severe colitis in UC. For UC, the occurrence of such
acute severe colitis remains unpredictable and does not help to
tailor the decision (13). In some series, however, the colectomy
rate was up to 20% of relapsing patients and is thus an important
limitation for this strategy (10). CD patients already having a
history of perianal fistulizing disease or intestinal strictures or
fistula and abdominal abscess are at risk of recurrence (12, 14).
Likewise, patients already operated on have a significant amount
of intestinal tissue damage, and the clinician should be very
careful not to increase it, particularly when there is a risk of
short bowel or a risk of subtotal colectomy or stoma (15). In the
published studies, the risk of relapse was particularly high in
patients with previous fistulizing perianal disease (14). Probably
explaining this, previous studies have illustrated that patients
experiencing full clinical closure of their perianal fistulas under
anti-TNF treatment usually keep signs of active inflammation in
their fistulous tracks and that the full healing and disappearance
of these fistulous tracks are very rare (16, 17). Likewise, previous
studies have shown a possible increased risk of relapse in
patients with a history of intestinal strictures or fistulas (12). In
those studies, the risk of developing new strictures, fistulas, or
abscess after anti-TNF of immunomudulator withdrawal was not
clearly indicated, but in the long-term follow-up of the STORI
cohort, with a median follow-up of 7 years, only 18% of the
patients developed major complications including the need for
surgical intestinal resection and new complex perianal fistulas.
According to this, the best candidates for treatment withdrawal
would be patients with no history of complex perianal disease;
no significant and recent stricture, fistula, or intra-abdominal
abscess; and no extensive surgical resection in CD (Table 1).
Likewise, patients with left-sided UC or proctitis could be better
candidates than those with pancolitis. Age is also important to
take into account as young patients will have to live longer with
their disease and are thus at increased risk of complications and
cumulative intestinal tissue damage.
A key element in case of relapse after treatment withdrawal
is the ability to re-capture the remission with the same drug.
This may be jeopardized by drug immunogenicity for biologics
and the development of anti-drug antibodies. These anti-drug
antibodies have been associated with transient drug withdrawal,
particularly with infliximab. This was particularly pronounced in
early experience with infliximab when only induction treatment
was given, followed by on-demand therapy. Scheduled treatment
and immunomodulator co-treatment have clearly decreased
immunogenicity, and in the STORI trial, only a few patients
developed anti-drug antibodies and none experienced acute
severe infusion reaction when resuming therapy (9). However, in
the STORI trial, due to this theoretical risk of allergic reaction
when restarting infliximab, a steroid infusion was given before
resuming infliximab and the first infusions were performed at a
slower pace, with a small amount of the drug infused during the
first hour. This is still our practice today, although no controlled
clinical trial validated this strategy. The risk of immunogenicity
with more recent biologics in the context of transient drug
withdrawal is less well-documented.
THE RISK OF ONGOING TREATMENT IN
IBD
The risk and tolerance of ongoing treatment is primarily
influenced by age and comorbidities (18). The risk of severe
infection under anti-TNF therapy has been shown to be
significantly higher in patients older than 65 years (19).
Likewise, anti-TNF and purine analogs are associated with
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an increased risk of lymphoma (20). The relative risk has
been estimated around 2 for anti-TNF and around 2–4 under
purine analogs, while it culminated at 4–6 under combined
therapy (20). However, this risk increases with age, leading
to a substantial number (albeit still low in absolute numbers)
of patients older than 65 years developing lymphoma under
these drugs (21). Purines have also been associated with other
forms of cancers, including skin cancers and urinary tract
cancers (22, 23). For these reasons, most clinicians now try
to decrease the use of purine analogs beyond 60–65 years of
age. The impact of anti-TNF and other biologics on other
cancers is not well-documented, apart from skin cancers and
perhaps melanoma under anti-TNF (24). Nevertheless, due to
the increased risk of cancers in aging people, drugs with a
systemic immunosuppressive effect should be used with caution.
Some comorbidities may also require attention. It includes
chronic obstructive pulmonary disease, which is associated with
an increased risk of bronchopulmonary superinfection (25).
Again, this may be increased by drugs having a systemic
immunosuppressive effect.
Another aspect is mild intolerance to the drug, like
some skin manifestations under anti-TNF therapy (26). Most
often, these manifestations are not sufficient per se to lead
to treatment interruption if the benefit of the treatment
remains significant (27). However, in some situations, it may
represent one argument among many others that may influence
the decision.
Therefore, from this point of view, the best candidates for
treatment withdrawal would be patients with some degree of
intolerance to the drug, or older patients (usually above 60–65
years of age) or those having comorbidities increasing the risk of
infection or cancer (Table 1).
THE COST OF ONGOING OR STOPPING
TREATMENT STRATEGIES
The cost of ongoing treatment will vary very much depending
on its nature: biologic therapy, biosimilar, or immunomodulator.
Although recent studies have demonstrated that a growing part
of the cost of management of IBD was linked to biologic therapy,
this did not take into account the spared costs due to a decrease of
hospitalizations or surgeries (28). In early studies with infliximab,
the drug was considered as cost-effective in CD but only for
one or a few years of therapy, the cost-effectiveness being not
demonstrated beyond this duration (29). A more recent study
specifically looked at the cost-effectiveness of a strategy of cycles
of biologic therapies, including periods of withdrawals when the
patients were in long-standing remission (30). This study showed
that the cost-effectiveness of continuous therapy was favorable
at some drug cost thresholds. Interestingly, with biosimilars,
these thresholds have recently been reached in several European
countries. The situation for biologics paid at the full price is
different, and for those, the continuous treatment is generally
less cost-effective than cycles of biologic treatment. The price of
FIGURE 1 | Proposed algorithm for treatment withdrawal decision in inflammatory bowel disease (IBD). This algorithm may provide a hierarchy among the questions
and factors that have to be assessed when contemplating treatment withdrawal in IBD. Some factors like the cost and the reimbursement may be specific to some
health care systems and jurisdiction.
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Due to personal views on the disease and its treatments, patients
may be more keen to accept consequences or complications of
the treatment or of the disease itself. The choice between medical
therapy and surgical therapy (which may be a consequence of
withdrawing therapy), for example, may vary among patients. In
a dedicated patients’ survey, it was shown that the risk of severe
infection or lymphoma that the patient would accept to be in
remission would vary very much but would be usually higher
than the one accepted by their doctors (31). More specifically,
concerning treatment withdrawal, it was shown that the patients
would usually prefer to stop immunomodulator than biologic
treatments and that the main reason for stopping therapy would
be the fear of side effects and particularly cancer (11). As far as
the risk of relapse that the patients would accept to be able to
stop one of their treatment, the majority would accept up to 25%
risk of relapse and up to 5% time with active disease to be able
to stop one of their treatments (biologic or immunomodulator)
(11). These numbers may serve as landmarks when considering
treatment withdrawal. However, some patients would not accept
any risk of relapse, while others would be ready to accept
very high risk to decrease their therapy (11). These questions
should be specifically asked to the patients before considering
treatment withdrawal.
Pregnancy represents a particular situation in which treatment
withdrawal is often contemplated or at least discussed. A
pregnant patient is usually very keen to stop therapy even before
the start of pregnancy. However, despite a relatively low amount
of evidence, most guidelines consider that almost all treatments
can be continued during pregnancy, except formethotrexate (32).
The consensus is that the worst thing for a pregnancy both for
the fetus and the mother is an uncontrolled disease and that
everything should be made to keep remission during pregnancy.
From this point of view, the best candidates for treatment
withdrawal would be the ones who, after a clear information
and understanding of not only the risks linked to treatment
withdrawal but also the consequences of continuing therapy,
choose to stop this treatment (Table 1).
INTEGRATIVE MODEL TO GUIDE
TREATMENT WITHDRAWAL IN IBD
The decision to withdraw a treatment in IBD is not an easy
one and is clearly multi-dimensional. There are several ways to
try and integrate these different dimensions. Most sophisticated
would include the development of a clinical decision support
system (33). Such tools have been developed for other chronic
diseases and can integrate several parameters and the positions
of several actors involved in the decision process, including
the patients. Artificial intelligence can be incorporated in those
tools to optimize the decision. They have yet to be developed
in the field of IBD. A simple tool could go through a
rough and semi-quantitative weighing of the different factors
and a graphical representation of the strength of arguments
in favor of stopping or continuing therapy (4). This model
has been proposed and illustrated in a previous publication
dealing with treatment withdrawal in CD. Alternatively, and
more simply, typical patients’ profiles can be created in
whom a decision of either treatment withdrawal or treatment
continuation could be the optimal choice (34). Another relatively
simple way to proceed would be to create an algorithm
incorporating the different dimensions governing the treatment
choice. This would require a hierarchy between the different
dimensions allowing for building an algorithm driven by
successive question. An example of such algorithm is presented
in Figure 1.
CONCLUSIONS
Systematic withdrawal of biologic therapy or immunomodulator
when the treatment target has been reached is not evidence
based and is not advisable. Nevertheless, for some subgroups
of patients, it may represent an option associated with
optimal benefit-risk and benefit-cost ratio. The decision to
withdraw treatment in IBD patients in remission should
thus be a tailored approach, mainly taking into account
the past clinical history of the patient, the current disease
state, the tolerance and risk of side effects as well as
patients’ preference and priorities. Optimal integration of all
these aspects may require specific tools incorporating artificial
intelligence. Simpler algorithms may also help the clinician in
routine practice.
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